Anti-Inflammatory Biologics Market to Surpass $166.28 Billion by 2029 | Key Trends & Insights

Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.

How Will the Anti-Inflammatory Biologics Market Grow by 2025 in Terms of Size and Growth?
In recent times, there has been significant growth in the size of the anti-inflammatory biologics market. The market, which is projected to increase from $108.11 billion in 2024 to $118.02 billion in 2025,will witness a compound annual growth rate (CAGR) of 9.2%. This expansion during the historic phase is attributable to an escalation in arthritis cases, amplified awareness about autoimmune diseases, the introduction of novel biologics, enhancements in healthcare infrastructure, and an increase in regulatory approval rates.

What Are the Estimated Growth Rates for the Anti-Inflammatory Biologics Industry Through 2029?
In the forthcoming years, the market size for anti-inflammatory biologics is projected to experience robust growth, reaching $166.28 billion by 2029 with a compound annual growth rate (CAGR) of 9.0%. This market expansion in the forecast period is associated with factors such as increased adoption of biologics, growing demand for targeted therapies, a trend towards long-term remission preferred by patients, enhanced use of biomarkers for disease tracking, and a rising need for personalized medicine. Key trends for the forecast period comprise progress in biologic drug creation, formulation of oral biologics for inflammation, advancements in drug delivery systems influenced by technology, progress in biosimilars, and improvements in diagnostic tools.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report

What Are the Strategic Drivers Boosting Anti-Inflammatory Biologics Market Performance?
The escalating occurrence of arthritis is anticipated to fuel the expansion of the anti-inflammatory biologics market in the future. Arthritis denotes joint inflammation or swelling often accompanied by pain, stiffness, and a decrease in mobility, which usually intensifies with age. One of the main reasons for the increasing occurrence of arthritis is the surge in obesity rates. Higher body weight results in extra pressure on the joints, leading to inflammation and gradual joint wear. Anti-inflammatory biologics greatly benefit arthritis patients as they target certain components of the immune system to lower inflammation, slow down joint damage, alleviate symptoms, and enhance physical function and life quality for those with moderate to severe arthritis. As per the Office for Health Improvement and Disparities, a government department based in the UK, there was a rise from 17.0% in 2021 to 17.6% in 2022 in the percentage of people aged 16 and over with a long-term Musculoskeletal (MSK) condition such as arthritis or a persistent back or joint issue, reported in March 2023. Therefore, the escalating occurrence of arthritis is stimulating the expansion of the anti-inflammatory biologics market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp

What Are the Segments in the Anti-Inflammatory Biologics Market?
The anti-inflammatory biologics market covered in this report is segmented -

1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous
3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes

Subsegments:
1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol
2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors
3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab
4) By T-Cell Inhibitors: Abatacept, Alefacept
5) By Other Drug Classes: Janus Kinase Inhibitors, Phosphodiesterase-4 Inhibitors, Sphingosine 1-Phosphate Receptor Modulators, Anti-IgE And Other Biologics

What Are the Key Adoption Trends in the Anti-Inflammatory Biologics Market?
Leading firms in the anti-inflammatory biologics sector are concentrating on the creation of innovative solutions like interleukin-6 (IL-6) receptor antagonists. These solutions are designed to specifically target chronic inflammatory diseases while minimizing side effects. IL-6 receptor antagonists are a type of biologic medication that work by blocking the IL-6 receptor, which then helps to lower inflammation and immune response in ailments like rheumatoid arthritis. An example of this came in February 2023 when Regeneron Pharmaceuticals Inc., a biotechnology company from the US, attained approval from the US Food and Drug Administration (FDA) for Kevzara. This solution is the only biologic treatment available for patients with polymyalgia rheumatica (PMR) who can't get adequate relief from corticosteroids. Kevzara is a fully human monoclonal antibody that inhibits the IL-6 receptor, consequently decreasing inflammation associated with PMR, an ailment that triggers muscle pain and stiffness primarily in elderly individuals. Unlike conventional steroids that can involve risks like osteoporosis and diabetes during prolonged usage, Kevzara offers a more specific, steroid-minimizing approach that bolsters improved patient results and long-term safety.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp

Which Companies Lead the Competitive Landscape of the Anti-Inflammatory Biologics Industry?
Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, Hansa Biopharma AB.

Where Are the Key Anti-Inflammatory Biologics Market Opportunities by Region?
North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

#Reach Out to Us#

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.